SCHEMBL5595124

SCHEMBL5595124

O=C(Nc1ccccc1)Nc1ccccc1S

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
EPHX1 P07099 1/20 0.65
TSHR P16473 1/20 0.65
EPHX2 P34913 1/20 0.65
CDK9 P50750 1/20 0.65
CLK4 Q9HAZ1 1/20 0.65
KMT2A Q03164 7/20 0.62
MEN1 O00255 6/20 0.62
NPC1 O15118 4/20 0.62
RAB9A P51151 4/20 0.62
LMNA P02545 2/20 0.62
HTT P42858 1/20 0.62
MDM4 O15151 2/20 0.59
MAPT P10636 4/20 0.59
KDM4E B2RXH2 3/20 0.59
GAA P10253 2/20 0.57
CASP3 P42574 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
POLB P06746 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21810514 0.86 SMN1; SMN2 (0.81) TP53SMN1; SMN2EPHX1TSHREPHX2
Diphenylurea SCHEMBL133103 0.81 SMN1; SMN2 (1.00) TP53SMN1; SMN2EPHX1TSHREPHX2
SCHEMBL30557281 0.80 SMN1; SMN2 (0.71) TP53SMN1; SMN2EPHX1TSHREPHX2
Diphenylurea SCHEMBL11596319 0.79 SMN1; SMN2 (0.77) TP53SMN1; SMN2EPHX1TSHREPHX2
SCHEMBL2364554 0.79 MDM4 (0.68) TP53SMN1; SMN2KMT2AMEN1NPC1
Diphenylurea SCHEMBL3037927 0.79 SMN1; SMN2 (0.94) TP53SMN1; SMN2EPHX1TSHREPHX2
Diphenylurea SCHEMBL28431956 0.79 SMN1; SMN2 (0.94) TP53SMN1; SMN2EPHX1TSHREPHX2
Diphenylurea SCHEMBL29392345 0.79 SMN1; SMN2 (0.94) TP53SMN1; SMN2EPHX1TSHREPHX2
SCHEMBL11059378 0.79 SMN1; SMN2 (0.94) TP53SMN1; SMN2EPHX1TSHREPHX2
Diphenylurea SCHEMBL30786615 0.79 SMN1; SMN2 (0.94) TP53SMN1; SMN2EPHX1TSHREPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0809492-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2007-01-24 EP disclosed
CN-1539816-A IL-8 receptor antagonists ʷ��˿�������ȳ�ķ���޹�˾ 2004-10-27 CN disclosed
EP-1185261-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-02-25 EP disclosed
EP-0896531-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-10-30 EP disclosed
US-20020128321-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2002-09-12 US disclosed
EP-1185261-A1 IL-8 RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-03-13 EP disclosed
US-6262113-B1 HYDROXY- OR MERCAPTO-PHENYLUREAS SMITHKLINE BEECHAM CORPORATION 2001-07-17 US disclosed
US-6211373-B1 Phenyl urea antagonists of the IL-8 receptor SMITHKLINE BEECHAM CORPORATION 2001-04-03 US disclosed
US-6180675-B1 THERAPY FOR CHEMOKINE SENSITIVE DISEASE; USING A AROMATIC (THIO)UREA COMPOUND SMITHKLINE BEECHAM CORPORATION 2001-01-30 US disclosed
WO-2000076495-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-21 WO disclosed
US-6005008-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1999-12-21 US disclosed
CN-1215990-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORP (US) 1999-05-05 CN disclosed
US-5886044-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1999-03-23 US disclosed
EP-0896531-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-17 EP disclosed
US-5780483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1998-07-14 US disclosed
EP-0809492-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-12-03 EP disclosed
WO-1997029743-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-21 WO disclosed
WO-1996025157-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1996-08-22 WO disclosed
US-4362706-A ORGANIC PHOSPHONIC ACID FMC CORPORATION (US) 1982-12-07 US disclosed
US-4307204-A CLOSED CELL FOAM OF POLYCHLOROPRENE OR ELASTOMER OF DIENE-ETHYLENE TERPOLYMER E. I. DU PONT DE NEMOURS AND COMPANY (US) 1981-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128321-A1 IL-8 receptor antagonists CXCL8, CCR8, IL1RN TP53 1373/4885SMN1; SMN2 4507/4885EPHX1 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.